NPR's Jon Hamilton reports on the controversy surrounding a drug widely used by diabetics. FDA advisers meet in Maryland today to discuss Rezulin, which was a big-seller when it came out in 1997 because it enabled many diabetics to reduce their need for insulin injections. But now there is serious concern that the drug significantly increases the risk of liver failure. Some are calling for a ban on the drug but others say that even with the risk of side effects, the benefits of Rezulin outweigh the potential harm.

Copyright © 1999 NPR. For personal, noncommercial use only. See Terms of Use. For other uses, prior permission required.

Copyright © 1999 NPR. All rights reserved. No quotes from the materials contained herein may be used in any media without attribution to NPR. This transcript is provided for personal, noncommercial use only, pursuant to our Terms of Use. Any other use requires NPR's prior permission. Visit our permissions page for further information.

NPR transcripts are created on a rush deadline by a contractor for NPR, and accuracy and availability may vary. This text may not be in its final form and may be updated or revised in the future. Please be aware that the authoritative record of NPR's programming is the audio.



Please keep your community civil. All comments must follow the Community rules and terms of use, and will be moderated prior to posting. NPR reserves the right to use the comments we receive, in whole or in part, and to use the commenter's name and location, in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.